(Q38022443)

27 August 2017

title

Adjuvant therapy of gastrointestinal stromal tumors (GIST). (English)

1 reference

27 August 2017

Elena Fumagalli

2

0 references

Alessandro Gronchi

object named as

Alessandro Gronchi

series ordinal

3

0 references

Paolo Giovanni Casali

object named as

Paolo G Casali

series ordinal

1

0 references

publication date

1 September 2012

1 reference

27 August 2017

number of pages

8

1 reference

Current Treatment Options in Oncology

inferred from page(s)

published in

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

277-284

1 reference

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Gastrointestinal stromal tumors: pathology and prognosis at different sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Risk stratification of patients diagnosed with gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Molecular characterization of pediatric gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Response evaluation of gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

The lessons of GIST--PET and PET/CT: a new paradigm for imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0198-0

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

21 January 2018

1 reference

12 December 2020

Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases

1 reference

12 December 2020

The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones.

1 reference

12 December 2020

Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour – The impact of tumour rupture on patient outcomes

1 reference

12 December 2020

Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad

1 reference

12 December 2020

10.1007/S11864-012-0198-0

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1026483806

0 references

1 reference